The full name of Anrotinib is Anrotinib Hydrochloride Capsules, which works as an anti-tumor growth with side effects such as bleeding, thromboembolism, high blood pressure, and abnormalities in liver and kidney function.
Anrotinib hydrochloride capsule is a multi-targeted receptor tyrosine kinase inhibitor with anti-tumor effects. It is indicated for the treatment of patients with non-small cell lung cancer, small cell lung cancer, adenoid soft tissue sarcoma, and clear cell sarcoma who meet specific criteria.
This drug may cause side effects such as hemorrhage, thromboembolism, hypertension, abnormalities in liver and kidney function, gastrointestinal discomfort, thyroid insufficiency, hyperlipidemia, and epilepsy. It is contraindicated in pregnant women, lactating women, allergic individuals, severe hepatic or renal insufficiency, centralized squamous lung cancer, or those at risk of hemoptysis.
The use of the drug should be evaluated and guided by a medical specialist, and the drug should be discontinued and medical attention should be sought if any side effects occur after use.